Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latiglutenase in symptomatic celiac disease
NCT04243551Phase 2Terminated
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Nov 2019
- Primary completion
- Oct 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing Latiglutenase with Placebo (2 arms). Primary endpoint: Symptom Severity Reduction at 6 months. Started Nov 2019; status: terminated.
02
Drugs
latiglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04243551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243551.